CH \$115.00.00 9791

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 Assignment ID: TMI201868

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Travere Therapeutics, Inc.		08/31/2023	Corporation: DELAWARE

RECEIVING PARTY DATA

Company Name:	Mirum Pharmaceuticals, Inc.
Street Address:	950 Tower Lane
Internal Address:	Suite 1050
City:	Foster City
State/Country:	CALIFORNIA
Postal Code:	94404
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 4

Property Type	Number	Word Mark
Serial Number:	97911202	CYPKEENA
Serial Number:	97911205	ONKEETX
Serial Number:	77652286	CHENODAL
Serial Number:	85884088	CHOLBAM

CORRESPONDENCE DATA

Fax Number: 2127046288

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (212)704-6125

Email: trademarks@troutman.com,Karl.Zielaznicki@troutman.com

Correspondent Name: Mr. Karl M. Zielaznicki

Address Line 1: 600 Peachtree Street, NE, Suite 3000

Address Line 4: Atlanta, GEORGIA 30308

ATTORNEY DOCKET NUMBER:	254409.000363
NAME OF SUBMITTER:	Eliza Cen
SIGNATURE:	Eliza Cen
DATE SIGNED:	05/01/2024

Total Attachments: 20

TRADEMARK
REEL: 008417 FRAME: 0163

source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page1.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page2.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page3.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page4.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page5.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page6.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page7.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page8.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page9.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page10.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page11.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page12.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page13.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page14.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page15.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page16.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page17.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page18.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page19.tif
source=[FINAL MERGE] Travere Assignment of Intellectual Property Executed#page20.tif

AMENDMENT TO ASSIGNMENT OF INTELLECTUAL PROPERTY

This AMENDMENT TO ASSIGNMENT OF INTELLECTUAL PROPERTY (this "Amendment to IP <u>Assignment</u>") effective August 31, 2023 (the "<u>Effective Date</u>") by and between Travere Therapeutics, Inc., a Delaware corporation with an address at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 ("<u>Assignor</u>") and Mirum Pharmaceuticals, Inc., a Delaware corporation with an address at 950 Tower Lane, Suite 1050, Foster City, CA 94404 ("<u>Assignee</u>"). Assignor and Assignee are individually referred to herein as a "<u>Party</u>," and collectively as the "<u>Parties</u>."

WHEREAS, Assignor and Assignee previously entered into an Asset Purchase Agreement dated July 16, 2023 (as may be amended from time to time, the "Purchase Agreement") and an Assignment of Intellectual Property effective August 31, 2023 (as may be amended from time to time, the "IP Assignment");

WHEREAS, in connection with the Purchase Agreement and pursuant to the IP Assignment, Assignor hereby assigned, transfers and conveys to Assignee, all of Assignor's worldwide right, title and interest in and to the in and to all of the Product IP, including without limitation, the Trademarks and Domain Names set forth on Attachment A attached thereto (collectively, as may be amended from time to time, the "Assigned IP");

WHEREAS, subsequent to the execution of the IP Assignment, the Parties became aware of certain issues with Section 1. <u>Transfer of Assigned IP</u> of the IP Assignment and as to the scope and accuracy of the Assigned IP on Attachment A and have agreed amend Section 1 <u>Transfer of Assigned IP</u> and amend and replace Attachment A with a new listing of Assigned IP (the "<u>Amended Attachment A</u>");

NOW, THEREFORE, pursuant to Purchase Agreement and the IP Assignment and in consideration of the promises and mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which is hereby, the Parties agree as follows:

1. Section 1, <u>Transfer of Assigned IP</u> of the IP Assignment is hereby amended and restated as follows:

Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee and its successors and assigns, and Assignee does hereby unconditionally accept: (a) all of Assignor's right, title and interest in and to the Assigned IP and any and all goodwill in or relating to the same along with that portion of Assignor's business in connection with which Assignor had a bona fide intention to use the Assigned IP including, without limitation, any Trademarks, to be held by Assignee for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns, designees, nominees and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; (b) all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to the Assignor with respect to any of the foregoing; (c) all claims, causes of action and enforcement rights, whether currently pending, filed, or otherwise, with respect to the Assigned IP, including all rights

to damages, injunctive relief and other remedies for past, current and future infringement of the Assigned IP; and (d) all other rights, privileges and protections of any kind whatsoever of Assignor accruing under any of the foregoing.

- 2. Attachment A of the IP Assignment is hereby amended and replaced with Amended Attachment A as annexed hereto.
- 3. The Parties expressly agree that all other provisions of the IP Assignment remain unaffected by this Amended IP Assignment.
- 4. This Amendment to IP Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement.

[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, the Parties have caused this Amendment to IP Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNOR:

TRAVERE THERAPEUTICS, INC.

Name Elizabeth Reed

Title: SVP, General Counsel & Secretary

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California County of San Diego

On <u>January 9, 2024</u> before me, <u>C. M. Parenteau. Notary Public</u> personally appeared <u>Elizabeth Reed</u> who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

C. M. PARENTEAU
Notary Public - California
San Dlego County
Commission # 2414992
My Comm. Expires Sep 5, 2026

[Signature Page to Amendment to Assignment of Intellectual Property]

(Seal)

ASSIGNEE:

MIRUM PHARMACEUTICALS, INC.

Name: Christopher Peetz

Title: President and Chief Executive Officer

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or yalidity of that document.

State of California
County of San Matco

On Feb 5, 2024 before me, Cyntha W Lee, Doing and personally appeared Cynthal Person (s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature _____(Seal)



[Signature Page to Amendment to Assignment of Intellectual Property]

Attachment A

Domain Names

- 1. AboutCTX.com
- 2. BehindtheBlur.com
- 3. Cholbam.com
- 4. CholbamHCP.com
- 5. LiverAtoZSD.com
- 6. <u>Understanding PBD-ZSD.com</u>
- 7. ZellwegerSpectrum.com
- 8. ZSDalliance.com
- 9. CTXrestore.com
- 10. Testcholestasis.com
- 11. Testctx.com
- 12. Cypkeena.com

Trademarks

CHOLBAM/KOLBAM

CHENODAL (wordmark)

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	204	\$	77/657786	10. Ion 00	2755000			
		•	00770011	17-3411-09	273278	07-Mar-10	Registered	Renewal: 02-Mar-30
Goods:		Pharmaceutical preparati	parations containing	chenodiol or derivati	ions containing chemodiol or derivatives thereof in oral docase form for the treatment of	or form for the treetman	at af an Hatanga	
					accommode and accommode	So total tol uic ucalific	all of gailstones.	
Canada	206CA	5	1539219	10-Aug-11	TMA840759	21-Jan-13	Registered	Renewel 71-Ion-78
							no includes	100110 W BI: 21-3011-20
Goods:		Pharmaceutical preparation	parations containing	chenodiol or derivati	ions containing chenodiol or derivatives thereof in oral dosage form for the treatment of callstones	ge form for the treatme	nt of galletones	

CHENODAL and Design

CHENKDAL

Next Action Due	·/ •	II/ d	r mannaccarical proparations containing enemodion (enemodeoxycholic acid) or derivatives thereof in oral dosage form for the treatment of gallstones and cerebrotendinous xanthomatosis.	n/a	s containing chenodiol (chenodeoxycholic acid) or derivatives thereof for the treatment of gallstones.
Status	Ahandoned	DOMINATION .	thereof in oral	Abandoned	thereof for the
Reg. Date	18-Im-13 Abandoned n/o		acid) or derivatives		acid) or derivatives
Reg. No.	4354250	1	cnenodeoxycholic		chenodeoxycholic a
Filing Date	20-Sep-09	ining of and died	uming chenodioi (27-May-20	ining chenodiol (
Appl. No.	77/830559	renorations conta	a cparations conta	88/936063	reparations conta
Class	5	Pharmacentical r	cerebrotendinous xanthomat	'n	Pharmaceutical preparations
Seed Ref.	205			288	
Country	U.S.		Goods:	U.S.	Goods:

9

CHENODAL REBRANDING MARKS

CHEVANU

	<u> </u>		<u> </u>
Next Action Due	n/a		s priminavoured preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of creebrotendinous xanthomatosis (CTX)
Status	Abandoned		disorders; phan
Reg. Date			unent of metabolic
Reg. No.		motions for the tree	metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)
Filing Date	12-May-20	armaceutical area	brotendinous xant
Appl. No.	88/912432	Pharmaceutical preparations: ph	lers, namely, cere
Classes	Š	Pharmaceutical	metabolic disord
Seed Ref.	285		
Country	U.S.		Goods:

CYPKEENA

Next Action Due	n/a		us, pnarmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of cerebrotendinous xanthomatosis (CTX)
Status	Abandoned n/a		disorders; pha
Reg. Date			atment of metabolic
Reg. No.			is, priarmaceutical preparations for the treat cerebrotendinous xanthomatosis (CTX)
Filing Date	12-May-20		annaceuncai prep protendinous xant
Appl. No.	88/912422	1.5	ers, namely, cerel
Classes	ν,	Dharmacautical arcacat	metabolic disorders, namely, o
Seed Ref.	284		
Country	U.S.		Goods:

CYPTAKEE

Country	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	287	5	88/912436	12-May-20			Abandoned n/a	/a
		Dharmacantical	owen conditions					
Goods:		metabolic disorders, namely,	i preparations, pri lers, namely, cere	armaceuncai prep brotendinous xant	 s. pharmaceunical preparations for the treat cerebrotendinous xanthomatosis (CTX) 	tment of metabolic	disorders; phan	name and proparations, piratmaceuncal preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of netabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)
					(27.2)			
U.S.	n/a	S	97/911,202	27-April-23			Pending In/a	1/a
		Dharmanantinal	nronomorotionot.				,	
20000		i idanisacouncai	preparations, pin	armaceutical prep	arations for the trea	tment of metabolic	disorders; phan	r manuacturing propagations, pital maceunical propagations for the treatment of metabolic disorders, pharmaceutical preparations for the treatment of
Connas.		metabolic disorders, namely,	ters, namely, cere	brotendinous xant	cerebrotendinous xanthomatosis (CTX)			
					/			

ONKEETX

						_		
Country Se	Seed Ref.	Classes	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Novt Antion Burn
+	†							TOY! WORD DAG
	286	ν.	88/912433	12-May-20			Abandoned n/a	n'a
	-	Pharmaceutical netabolic disord	preparations; pha ers, namely, cereb	rmaceutical preparotendinous xant	Pharmaceutical preparations; pharmaceutical preparations for the treametabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	trnent of metabolic	disorders; phar	Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of netabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)
	4/1	ų						
_	n/a	ر م	97/911,205	27-April-23			Pending n/a	z/r
	H	Pharmaceutical preparations; p metabolic disorders, namely, cer	preparations; pha	rmaceutical preparetion	Pharmaceutical preparations; pharmaceutical preparations for the treametabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	tment of metabolic	disorders; phar	pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of erebrotendinous xanthomatoris (CTX)

mark	
Word	
rks and trademark applications (
and trademark	
and	
trademarks a	
trad	
isting	

Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	215	5	85/884088	22-Mar-13	4752361	09_Im_1\$	Danistored	Domoniol, 00 L 05
Goods:	ds:	Pharmaceutical	preparations for u	ise in treatment of	findividuals with m	Pharmaceutical preparations for use in treatment of individuals with mimany and samudan defent in Line 1911.	Action in Li	Actiowal: 09-Jun-23
Argentina	226AR	5	3433793	18-Aug-15	2817870	12-In1-16	Domintonad	Defend synthesis.
Goods:	ds:	Pharmaceutical	preparations for u	ise in treatment or	findividuals with m	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile and a mathemia	v defects in hi	Decialation of USE: 12-Jul-26
Australia	21SPAU	5	A0052495	13-Aug-15	1265512	13-Amg-15	Dociotomy	ic actu synthesis.
Goods:	ds:	Pharmaceutical	preparations for u	ise in treatment of	findividuals with m	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defeate in his point and secon	Aefects in hi	Aefects in hilp acid must cit
Brazil	220BR	5	909857865	19-Aug-15	909857865	31-Oct-17	Registered	Registered Denamel 21 Oct 27
Goods:	ds:	Pharmaceutical	preparations for u	ise in treatment of	Findividuals with on	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile acid anathesis	v defects in hi	Incircual, 31-Oct-2/
Canada	225CA	5	1742193	18-Aug-15	TMA1032314	26-Jun-19	Registered	Renewal: 26-11m-20
Goods:	ds:	Pharmaceutical	preparations for t	ise in treatment of	individuals with m	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile and a material	defects in hi	to oold amsteria
Chile	221CL	5	1.166.449	14-A110-15	1 202 404	15 Apr 16	y descens III DI	ic acid synthesis.
spool	ds:	Pharmaceutical	Orenometrone for		1. 1. 1. 1.	01-1/12-01	Registered	Registered Renewal: 15-Apr-26
		i namavullvan	pichai anons loi	ise in treatment o	r individuals with p	r mannaccurical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.	y defects in bi	le acid synthesis.
Colombia	215PCO	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Registered Renewal: 13-Aug-25
Goods:	ds:	Pharmaceutical	preparations for t	ise in treatment of	findividuals with pa	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile acid synthesis	v defects in hi	le acid conthesis
Madrid Protocol	215WP	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Renewal: 13-4m-75
Goods:	ds:	Pharmaceutical	preparations for u	ise in treatment of	findividuals with m	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile acid sunthesis	v defects in hi	Itomowal, 13-Aug-23
Israel	215PIL	5	A0052495	13-Aug-15	1265512	13-A110-15	Posistered	Registered Benevini 12 A of
		Pharmaceutical	preparations for t	ise in treatment of	findividuals with pr	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis	y defects in bi	le acid synthesis
Japan	215PJP	5	A0052495	13-Aug-15	1265512	13-Aug-15	Registered	Registered Renewal: 13-Ano-25
		Pharmaceutical	preparations for u	ise in treatment of	individuals with or	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in hile acid exertheris	v defects in hi	le avid evertherin
Korea	215PKR	5	A0052495	13-Aug-15	1265512	13-A110-15	Registered	Denamal: 12 Aug. 25
Goods:	ds:	Pharmaceutical	preparations for u	Ise in treatment of	individuals with m	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defeats in Line 13.44	defeate in hi	Noticwal, 13-Aug-23
Mexico	215PMX	5	A0052495	13-Aug-15		Process are Comme	Abandoned	ic acid synthesis.
Goods:	ds:	Pharmaceutical	preparations for t	use in treatment of	findividuals with pa	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.	y defects in bi	le acid synthesis.

TRADEMARK

REEL: 008417 FRAME: 0173

Registered Renewal: 13-Aug-25	e acid cunthesis	Registered Renewal 01-11-1-25	a soid synthesis	to actu ay itulicala.	Registered Renewal: 30-Apr-26	e acid conthesis		Registered Renewal: 07-Oct-25	le acid synthesis.
Registered	defects in hil	Registered	defects in hi	COLOCUS III OI	Registered	defects in hil		Registered	y defects in bil
13-Aug-15	ical preparations for use in treatment of individuals with primary and secondary defects in hile acid countracts	28-Feb-16	ical preparations for use in treatment of individuals with primary and secondary defects in hile axid anotherin	mora son com	01-May-16	ical preparations for use in treatment of individuals with primary and secondary defects in hile acid synthesis		13-Jul-16	ical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.
1265512	individuals with pri	1437000861	individuals with pri		01766681	individuals with ori	041770	241379	individuals with pri
13-Aug-15	e in treatment of	25-Oct-15	e in treatment of		14-Aug-15	e in treatment of	07 Oct 15	0/-00-13	e in treatment of
A0052495	reparations for us	1437000861	reparations for us		104047933 14-Aug-15	reparations for us	241370	21017	reparations for us
5	Pharmaceutical p	5	Pharmaceutical p		5	Pharmaceutical p	۶	ļ	Pharmaceutical p
215PNZ	ls:	222SA	ls:		224 I.W	ls:	223AF		ls:
New Zealand	Goods:	Saudi Arabia	Goods:		i aiwan	Goods:	United Arab	Emirates	Goods:

REEL: 008417 FRAME: 0174

ASSIGNMENT OF INTELLECTUAL PROPERTY

This **Assignment of Intellectual Property** (this "<u>Assignment</u>") is made and entered into as of August 31, 2023 (the "<u>Effective Date</u>") by and between Travere Therapeutics, Inc., a Delaware corporation with an address at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 ("<u>Assignor</u>") and Mirum Pharmaceuticals, Inc., a Delaware corporation with an address at 950 Tower Lane, Suite 1050, Foster City, CA 94404 ("<u>Assignee</u>"). Assignor and Assignee are individually referred to herein as a "Party," and collectively as the "Parties."

WHEREAS, Assignor and Assignee have entered into the Asset Purchase Agreement dated July 16, 2023 (as may be amended from time to time, the "<u>Purchase Agreement</u>");

WHEREAS, capitalized terms used and not otherwise defined herein have the meanings ascribed thereto in the Purchase Agreement;

WHEREAS, in connection with the Purchase Agreement, the parties to the Purchase Agreement desire that Assignor transfer to Assignee all of the right, title and interest of Assignor in and to the Product IP, including without limitation the Trademarks and Domain Names set forth on Attachment A attached hereto (collectively, the "Assigned IP"); and

WHEREAS, Assignee wishes to acquire all of Assignor's right, title and interest in and to the Assigned IP, and Assignor wishes to assign such right, title and interest in and to such Assigned IP to Assignee.

Now, Therefore, in consideration of the mutual promises hereinafter set forth and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:

- 1. <u>Transfer of Assigned IP</u>. Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee and its successors and assigns, and Assignee does hereby unconditionally accept: (a) all of Assignor's right, title and interest in and to the Assigned IP; (b) all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to the Assignor with respect to any of the foregoing; (c) all claims, causes of action and enforcement rights, whether currently pending, filed, or otherwise, with respect to the Assigned IP, including all rights to damages, injunctive relief and other remedies for past, current and future infringement of the Assigned IP; and (d) all other rights, privileges and protections of any kind whatsoever of Assignor accruing under any of the foregoing.
- 2. Proxy Service and Electronic Transfer for Domain Names. Assignor hereby authorizes and requests, or will cause any proxy service that registered any of the domain names included in the Assigned IP on Assignor's behalf to authorize or request, the applicable registration authority to transfer such domain names from Assignor or such proxy service, as the case may be, to Assignee. Assignor agrees to cooperate with Assignee to initiate and complete the transfer process in relation to such domain names electronically from Assignor's account to Assignee's account and servers.

- 3. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, at Assignee's expense, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned IP in Assignee, its successors and assigns. Assignor hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks of the United States Patent and Trademark Office, the Commissioner for Copyrights of the United States Copyright Office and any other Governmental Entity to record and register this Assignment upon request by Assignee. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead solely to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance and perfection of patent, trademark, copyright or other intellectual property registrations or any other legal protection thereon with the same legal force and effect as if executed by such Assignor.
- 4. <u>Entire Agreement</u>. This Assignment and the Purchase Agreement reflect the entire understanding of the Parties relating to the sale, assignment, transfer, conveyance and delivery of the Assigned IP from Assignor to Assignee, and supersede all prior agreements, understandings or letters of intent between or among the Parties regarding the subject matter of this Assignment and the Purchase Agreement.
- 5. <u>Successors and Assigns</u>. This Assignment shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.
- 6. <u>Governing Law</u>. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to any conflict of law principles.
- 7. <u>Arbitration of Disputes</u>. Section 10.8 of the Purchase Agreement is hereby incorporated by reference *mutatis mutandis*.
- 8. Severability. Whenever possible, each provision or portion of any provision of this Assignment shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Assignment is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Assignment shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.
- 9. <u>Counterparts</u>. This Assignment may be executed in several counterparts, each of which will constitute an original and all of which, when taken together, will constitute one agreement. This Assignment may be executed by .PDF or by other means of electronic signature (including DocuSign), and the exchange of a fully executed Assignment (in counterparts or otherwise) by electronic means in .PDF format shall in each case create a valid and binding obligation of the Party executing the same.

10. <u>Purchase Agreement Shall Control</u>. Nothing in this Assignment shall change, amend, limit, extend or alter (nor shall it be deemed or construed as changing, amending, extending or altering) the terms or conditions of the Purchase Agreement or any liability or obligation of the Assignor or Assignee arising under the Purchase Agreement, which shall govern the representations, warranties and obligations of the Parties with respect to the Assigned IP. The terms of the Purchase Agreement are incorporated herein by this reference, and in the event that any of the provisions of this Assignment are determined to conflict with the terms of the Purchase Agreement, the terms of the Purchase Agreement shall control.

[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNOR:

TRAVERE THERAPEUTICS, INC.

By: Cric Dube

Name: Eric Dube

Title: President and Chief Executive Officer

[Signature Page to Assignment of Intellectual Property]

ASSIGNEE: MIRUM PHARMACEUTICALS, IN

Ву: ______

Name: Christopher Peetz

Title: President and Chief Executive Officer

[Signature Page to Assignment of Intellectual Property]

Attachment A

Domain Names

- 1. AboutCTX.com
- 2. BehindtheBlur.com
- 3. Cholbam.com
- 4. CholbamHCP.com
- 5. LiverAtoZSD.com
- 6. UnderstandingPBD-ZSD.com
- 7. ZellwegerSpectrum.com
- 8. ZSDalliance.com
- 9. CTXrestore.com
- 10. Testcholestasis.com
- 11. Testctx.com
- 12. Cypkeena.com

Trademarks

CHOLBAM/KOLBAM

CHENODAL (wordmark)

Goods:	Canada	Goods:	U.S.	Country
	206CA	ds:	204	Seed Ref.
Pharmaceutical prep	5	Pharmaceutical prep	5	Class
arations containing o	1539219	arations containing o	77/652286	Appl. No.
chenodiol or derivati	10-Aug-11	henodiol or derivati	19-Jan-09	Filing Date
Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.	TMA840759	Pharmaceutical preparations containing chenodiol or derivatives thereof in oral dosage form for the treatment of gallstones.	3755928	Reg. No.
ge form for the treatmo	21-Jan-13	ge form for the treatmo	02-Mar-10	Reg. Date
ent of gallstones.	Registered	ent of gallstones.	Registered	Status
	Registered Renewal: 21-Jan-28		Registered Renewal: 02-Mar-30	Next Action Due

CHENODAL and Design



		0						
Country	Seed Ref.	Class	Appl. No.	Filing Date	Reg. No.	Reg. Date	Status	Next Action Due
U.S.	205	5	77/830559 20-Sep-09	20-Sep-09	4354250	18-Jun-13	Abandoned n/a	n/a
Goods:	ds:	Pharmaceutical preparations con cerebrotendinous xanthomatosis	preparations conta s xanthomatosis.	ining chenodiol (chenodeoxycholic a	icid) or derivatives	thereof in oral	Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof in oral dosage form for the treatment of gallstones and cerebrotendinous xanthomatosis.
U.S.	288	5	88/936063	27-May-20			Allowed	Statement of Use – FINAL: 10-Nov-23
Goods:	ds:	Pharmaceutical 1	preparations conta	ining chenodiol (chenodeoxycholic a	icid) or derivatives	thereof for the	Pharmaceutical preparations containing chenodiol (chenodeoxycholic acid) or derivatives thereof for the treatment of gallstones

CHENODAL REBRANDING MARKS

CHEVANU

Goods	U.S.	Country
	285	Seed Ref.
Pharmaceutical p metabolic disord	5	Classes
ers, namely, cerei	88/912432	Appl. No.
Pharmaceutical preparations; pharmaceutical preparations for the tre metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	12-May-20	Filing Date
rations for the treat thomatosis (CTX)		Reg. No.
ment of metabolic d		Reg. Date
lisorders; pharr	Allowed	Status
naceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of polic disorders, namely, cerebrotendinous xanthomatosis (CTX)	Statement of Use/5 th Extension Request: 27-Oct-23	Next Action Due

CYPKEENA

Goods	U.S.	Country
	284	Seed Ref.
Pharmaceutical pmetabolic disord	5	Classes
oreparations; pharers, namely, cere	88/912422	Appl. No.
Pharmaceutical preparations; pharmaceutical preparations for the tremetabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	12-May-20	Filing Date
rations for the treat thomatosis (CTX)		Reg. No.
Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)		Reg. Date
lisorders; pharr	Allowed	Status
ders; pharmaceutical preparations for the treatment of	Statement of Use/5 th Extension Request: 27-Oct-23	Next Action Due

CYPTAKEE

Goods	U.S.	Country
ds:	287	Seed Ref.
Pharmaceutical pmetabolic disord	5	Classes
oreparations; pharers, namely, cere	88/912436	Appl. No.
harmaceutical preparations; pharmaceutical preparations for the tre netabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	12-May-20	Filing Date
rations for the treature thomatosis (CTX)		Reg. No.
nent of metabolic d		Reg. Date
isorders; pharm	Allowed	Status
Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)	Statement of Use/5th Extension Request: 27-Oct-23	Next Action Due

ONKEETX

Goods	U.S.	Country
ds:	286	Seed Ref.
Pharmaceutical pmetabolic disord	5	Classes
harmaceutical preparations; pharmaceutical netabolic disorders, namely, cerebrotendinou	88/912433	Appl. No.
maceutical prepa brotendinous xan	12-May-20	Filing Date
Pharmaceutical preparations; pharmaceutical preparations for the treatment of metabolic disc metabolic disorders, namely, cerebrotendinous xanthomatosis (CTX)		Reg. No.
nent of metabolic d		Reg. Date
isorders; pharr	Allowed	<u>Status</u>
sorders; pharmaceutical preparations for the treatment of	Statement of Use/5 th Extension Request: 27-Oct-23	Next Action Due

Existing trademarks and trademark applications (Wordmark)

e acid synthesis.	y defects in bile	mary and secondar	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.	se in treatment of	reparations for us	Pharmaceutical p	ds:	Goods:
	Abandoned			13-Aug-15	A0052495	5	215PMX	Mexico
e acid synthe	y defects in bile acid synthesis.	mary and secondar	Pharmaceutical preparations for use in treatment of individuals with primary and secondar	se in treatment of	reparations for us	Pharmaceutical p	ds:	Goods
Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215PKR	Korea
defects in bile acid synthesis	y defects in bik	mary and secondar	in treatment of individuals with primary and secondar	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p		
Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215PJP	Japan
e acid synthesis	y defects in bile	mary and secondar	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis	se in treatment of	reparations for us	Pharmaceutical p		
Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215PIL	Israel
e acid synthesis.	y defects in bik	mary and secondar	in treatment of individuals with primary and secondary defects in bile acid synthesis	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods
Registered Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215WP	Madrid Protocol
y defects in bile acid synthesis.	y defects in bile	mary and secondar	in treatment of individuals with primary and secondar	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods
Registered Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215PCO	Colombia
y defects in bile acid synthesis.	y defects in bile	mary and secondar	in treatment of individuals with primary and secondar	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods:
Registered Renewal: 15-Apr-26	Registered	15-Apr-16	1166449	14-Aug-15	1166449	5	221CL	Chile
e acid synthesis.	y defects in bik	mary and secondar	in treatment of individuals with primary and secondary defects in bile acid synthesis.	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods
Registered Renewal: 26-Jun-29	Registered	26-Jun-19	TMA1032314	18-Aug-15	1742193	5	225CA	Canada
y defects in bile acid synthesis.	y defects in bile	mary and secondar	Pharmaceutical preparations for use in treatment of individuals with primary and secondar	se in treatment of	reparations for us	Pharmaceutical p	ds:	Goods
Renewal: 31-Oct-27	Registered	31-Oct-17	909857865	19-Aug-15	909857865	5	220BR	Brazil
defects in bile acid synthesis.	y defects in bile	mary and secondar	in treatment of individuals with primary and secondar	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods
Renewal: 13-Aug-25	Registered	13-Aug-15	1265512	13-Aug-15	A0052495	5	215PAU	Australia
y defects in bile acid synthesis.	y defects in bile		Pharmaceutical preparations for use in treatment of individuals with primary and secondar	se in treatment of	reparations for us	Pharmaceutical p	ds:	Goods:
Declaration of Use: 12-Jul-26	Registered	12-Jul-16	2817870	18-Aug-15	3433793	5	226AR	Argentina
y defects in bile acid synthesis.	y defects in bile	mary and secondar	in treatment of individuals with primary and secondar		Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods:
Renewal: 25-Mar-23	Registered	22-Aug-13	UK00911686177	25-Mar-13	011686177	5	216GB	United Kingdom
y defects in bile acid synthesis.	y defects in bik	mary and secondar	in treatment of individuals with primary and secondar		Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods
Registered Renewal: 25-Mar-23	Registered	22-Aug-13	011686177	25-Mar-13	011686177	5	216EM	European Union
e acid synthesis.	y defects in bile	mary and secondar	in treatment of individuals with primary and secondary defects in bile acid synthesis	se in treatment of	Pharmaceutical preparations for use	Pharmaceutical p	ds:	Goods:
Renewal: 09-Jun-25	Registered	09-Jun-15	4752361	22-Mar-13	85/884088	5	215	.S.U
Next Action Due	Status	Reg. Date	Reg. No.	Filing Date	Appl. No.	Class	Seed Ref.	Country
								•

Goods:	United Arab 22 Emirates 22	Goods:	Taiwan 22	Goods:	Saudi Arabia 22	Goods:	New Zealand 215PNZ
P	223AE	P	224TW	Į.	222SA	P	5PNZ
harmaceutical pi	5	harmaceutical p	5	harmaceutical p	5	harmaceutical p	5
reparations for us	241379	reparations for us	104047933	reparations for us	1437000861	reparations for us	A0052495
e in treatment of	07-Oct-15	e in treatment of	104047933 14-Aug-15	e in treatment of	1437000861 25-Oct-15 1437000861	e in treatment of	13-Aug-15
individuals with pri	241379	individuals with pri	01766681	individuals with pri	1437000861	individuals with pri	1265512
Pharmaceutical preparations for use in treatment of individuals with primary and secondary	13-Jul-16	Pharmaceutical preparations for use in treatment of individuals with primary and secondary	01-May-16	Pharmaceutical preparations for use in treatment of individuals with primary and secondary	28-Feb-16	Pharmaceutical preparations for use in treatment of individuals with primary and secondary defects in bile acid synthesis.	13-Aug-15
y defects in bil	Registered	y defects in bil	Registered	y defects in bil	Registered	y defects in bil	Registered
defects in bile acid synthesis.	Registered Renewal: 07-Oct-25	defects in bile acid synthesis.	Registered Renewal: 30-Apr-26	defects in bile acid synthesis.	Registered Renewal: 01-Jul-25	le acid synthesis.	Registered Renewal: 13-Aug-25

TRADEMARK
RECORDED: 05/01/2024 REEL: 008417 FRAME: 0184